NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INSM stock has increased by 39.2% and is now trading at $29.57. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.02. The biopharmaceutical company had revenue of $36.90 million for the quarter, compared to analyst estimates of $34.81 million. Insmed had a negative return on equity of 87.35% and a negative net margin of 162.82%. The business's revenue for the quarter was up 68.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.96) EPS. View Insmed's earnings history.

8 Wall Street analysts have issued 1 year price objectives for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 42.0% from the stock's current price. View analysts' price targets for Insmed.

News coverage about INSM stock has been trending negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Insmed earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View the latest news about Insmed.

Some companies that are related to Insmed include Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR) and Reata Pharmaceuticals (RETA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $29.57.

Insmed has a market capitalization of $2.99 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]